New Delhi News

Advanced Gastric Carcinoma Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Advanced Gastric Carcinoma Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

January 23
19:33 2023
Advanced Gastric Carcinoma Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Advanced Gastric Carcinoma Pipeline Insight 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including Advanced Gastric Carcinoma clinical trials and nonclinical stage products. It also covers the Advanced Gastric Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Advanced Gastric Carcinoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Advanced Gastric Carcinoma NDA approvals (if any), and product development activities comprising the technology, Advanced Gastric Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Advanced Gastric Carcinoma Pipeline Report

 

  • DelveInsight’s Advanced Gastric Carcinoma Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Gastric Carcinoma.

 

  • The leading Advanced Gastric Carcinoma Companies includes Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical,  CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, and others.

 

  • Promising Advanced Gastric Carcinoma Pipeline Therapies include pemetrexed, oxaliplatin, cisplatin, Everolimus, Nivolumab, Ipilimumab, Relatlimab, Docetaxel, Capecitabine, Cisplatin, Bevacizumab, AUY922, Docetaxel, Irinotecan, apatinib, and others.

 

To explore more information on the latest breakthroughs in the Advanced Gastric Carcinoma Pipeline treatment landscape of the report, click here @ Advanced Gastric Carcinoma Pipeline Outlook

 

Advanced Gastric Carcinoma Overview

Advanced stomach cancer means that a cancer that began in the stomach has spread to at least one other part of the body, such as the liver or lungs. Stomach cancer can spread to the: liver, lungs, lymph nodes, and tissue lining the abdominal cavity (peritoneum). The symptoms of advanced stomach cancer depend on what part of the body the cancer has spread to. The most common symptoms of stomach cancer include: unexplained weight loss, feeling and being sick, stomach pain, difficulty swallowing, feeling tired. Advanced stage means your stomach cancer has spread. External radiotherapy can help to control your cancer and reduce symptoms. Treatments such as chemotherapy or radiotherapy or targeted drugs can sometimes help to reduce symptoms. Other treatments such as laser therapy or stents can treat a blockage in the stomach. Surgery can help relieve symptoms of advanced stomach cancer if your cancer is causing a blockage. Laser therapy uses hot beams of light to burn away cancer cells. This can help control symptoms of advanced stomach cancer.

 

Advanced Gastric Carcinoma Emerging Drugs Profile

 

Camrelizumab: Jiangsu Hengrui Medicine

 

Camrelizumab (formerly known as HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death-1 receptor. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced gastric or gastroesophageal junction adenocarcinoma.

 

Pamiparib: BeiGene

 

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

 

Advanced Gastric Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Advanced Gastric Carcinoma. The companies which have their Advanced Gastric Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.

 

Request a sample and discover the recent advances in Advanced Gastric Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Gastric Carcinoma Treatment Landscape

 

Scope of the Advanced Gastric Carcinoma Pipeline Report

 

  • Coverage- Global

 

  • Advanced Gastric Carcinoma Companies- Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical,  CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, and others.

 

  • Advanced Gastric Carcinoma Pipeline Therapies- pemetrexed, oxaliplatin, cisplatin, Everolimus, Nivolumab, Ipilimumab, Relatlimab, Docetaxel, Capecitabine, Cisplatin, Bevacizumab, AUY922, Docetaxel, Irinotecan, apatinib, and others.

 

  • Advanced Gastric Carcinoma Pipeline Segmentation: Phases, Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Advanced Gastric Carcinoma Market Drivers and Advanced Gastric Carcinoma Market Barriers, click here @ Advanced Gastric Carcinoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Advanced Gastric Carcinoma Executive Summary
  3. Advanced Gastric Carcinoma: Overview
  4. Advanced Gastric Carcinoma Pipeline Therapeutics
  5. Advanced Gastric Carcinoma Therapeutic Assessment
  6. Advanced Gastric Carcinoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Camrelizumab: Jiangsu Hengrui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Pamiparib: BeiGene
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Venadaparib: Idience
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Gastric Carcinoma Key Companies
  21. Advanced Gastric Carcinoma Key Products
  22. Advanced Gastric Carcinoma- Unmet Needs
  23. Advanced Gastric Carcinoma- Market Drivers and Barriers
  24. Advanced Gastric Carcinoma- Future Perspectives and Conclusion
  25. Advanced Gastric Carcinoma Analyst Views
  26. Advanced Gastric Carcinoma Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Advanced Gastric Carcinoma Mergers and acquisitions, Advanced Gastric Carcinoma licensing activities @ Advanced Gastric Carcinoma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Related Articles